K. Strand

Expression biomarkers for clinical efficacy and outcome prediction in cancer.

J. Strovel, M. Augustus, H. Khalak, 2006, Pharmacogenomics.

Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor.

J. Strovel, Y. Hayashi, H. Hirai, 2011, Cancer letters.

A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells

Melissa A. Wilson, S. Chrysogelos, J M McInerney, 2001, Journal of cellular biochemistry.

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model

J. Strovel, M. Taniwaki, Y. Hayashi, 2011, Blood cancer journal.

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model

J. Strovel, M. Taniwaki, Y. Hayashi, 2011, Blood cancer journal.